Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Pacira BioSciences Inc shares valued at $20,034 were purchased by BIGAL MARCELO on Aug 16 ’24. At $13.25 per share, BIGAL MARCELO acquired 1,512 shares. The insider’s holdings grew to 10,142 shares worth approximately $0.15 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Brege Laura purchased 1,000 shares, netting a total of over 12,810 in proceeds. Following the buying of shares at $12.81 each, the insider now holds 17,552 shares.
Before that, YANG MICHAEL J. had added 2,000 shares to its account. In a trade valued at $25,800, the Director bought Pacira BioSciences Inc shares for $12.90 each. Upon closing the transaction, the insider’s holdings increased to 2,000 shares, worth approximately $0.11 million.
As published in a research note from Truist on August 13, 2024, Pacira BioSciences Inc [PCRX] has been rated down from a Buy to a Sell and the price target has been revised to $8 from $30. Analysts at RBC Capital Mkts downgraded the stock from ‘”an Outperform”‘ to ‘”a Sector perform”‘ outlook in a report released in mid August. As of August 12, 2024, Raymond James has decreased its “an Outperform” rating to a “Mkt perform” for PCRX. Earlier on August 12, 2024, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for PCRX stock which previously was a “an Overweight”.
Analyzing PCRX Stock Performance
During the last five days, there has been a surge of approximately 7.58%. Over the course of the year, Pacira BioSciences Inc shares have dropped approximately -55.84%. Shares of the company reached a 52-week high of $35.95 on 01/08/24 and a 52-week low of $11.16 on 08/13/24. A 50-day SMA is recorded $20.15, while a 200-day SMA reached $27.23. Nevertheless, trading volume fell to 0.81 million shares from 0.66 million shares the previous day.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
According to the 24-hour chart, there is a support level at 14.52, which, if violated, would cause prices to drop to 14.15. In the upper region, resistance lies at 15.12. The next price resistance is at 15.35. RSI (Relative Strength Index) is 40.36 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.13, which suggests the price will increase in the coming days. Percent R is at 70.89%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
